Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925990 | 1.00 | ACHE (0.32) | ACHEALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL4917712 | 0.82 | MEN1 (0.32) | MEN1GAAKMT2A | |
| SCHEMBL4917709 | 0.82 | MEN1 (0.32) | MEN1GAAKMT2A | |
| SCHEMBL7831687 | 0.64 | LMNA (0.34) | ALDH1A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL2661782 | 0.64 | NPSR1 (0.40) | ALDH1A1KDM4EMEN1LMNAPOLB | |
| SCHEMBL4915529 | 0.64 | NPSR1 (0.37) | KDM4EPOLBMAPTKMT2A | |
| SCHEMBL13933157 | 0.62 | MEN1 (0.35) | ACHEALDH1A1MEN1LMNAPOLB | |
| SCHEMBL7383326 | 0.62 | ACHE (0.37) | ACHEALDH1A1MEN1LMNAPOLB | |
| SCHEMBL2662587 | 0.61 | MAPK1 (0.35) | — | |
| SCHEMBL28957621 | 0.59 | PGR (0.39) | KDM4EMEN1LMNAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | ACHE 41/4885ALDH1A1 442/4885KDM4E 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.